DARU Journal of Pharmaceutical Sciences最新文献

{"title":"Proposed echocardiography-guided flowchart for calcium channel blocker overdose: distinguishing vasoplegia from cardiogenic shock.","authors":"Omid Mehrpour, Jeffrey Brent","doi":"10.1007/s40199-026-00596-z","DOIUrl":"10.1007/s40199-026-00596-z","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy of a novel cannabidiol and bevacizumab combination in non-small cell lung cancer.","authors":"Abdul Qadir, Zurqa Khalid, Ayesha Kashmala Ghauri, Muhammad Hamza Dawood, Usama Manzoor, Habib Ur Rehman","doi":"10.1007/s40199-026-00599-w","DOIUrl":"10.1007/s40199-026-00599-w","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential of cinnamic acid analogues in alzheimer's disease.","authors":"Padmaja Patil, Shreyash Jaiswal, Arati Prabhu","doi":"10.1007/s40199-026-00593-2","DOIUrl":"10.1007/s40199-026-00593-2","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the therapeutic potential of Farnesol against Parkinson's disease: insights from molecular Docking and animal studies.","authors":"Hirok Jyoti Baishya, Jyutia Nargish, Piyong Sola","doi":"10.1007/s40199-026-00592-3","DOIUrl":"10.1007/s40199-026-00592-3","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is a chronic neurodegenerative disorder that progressively worsens over an individual's lifetime. Current treatments primarily address the symptoms rather than the underlying cause of the disease, and many patients report adverse side effects from the medications used. Nature offers a wealth of medicinal plants, among which Ocimum tenuiflorum stands out for its potential to treat various health issues.</p><p><strong>Objective: </strong>The objective of the study is to identify an effective phytochemical from Ocimum tenuiflorum using in silico and in vivo methods for the management of PD.</p><p><strong>Methods: </strong>Molecular docking was employed to identify potential phytochemicals in Ocimum tenuiflorum that target the mTOR pathway. Farnesol was chosen for further evaluation based on its docking score, blood-brain barrier permeability, and pharmacokinetic properties. In vivo studies were carried out using rotenone-induced PD models in mice, and the effects of farnesol on behavioral changes, oxidative stress, and histopathological alterations were examined.</p><p><strong>Results: </strong>Farnesol showed a high docking score and the ability to cross the blood-brain barrier. In vivo studies revealed that farnesol treatment enhanced locomotor activity, lowered cataleptic scores, and increased antioxidant enzyme activity (SOD) in the brain. The strongest antioxidant effect was achieved by the high dose, which brought the levels of MDA and SOD near to the control 8.3% and 95.4% respectively, as compared to the disease group. Additionally, farnesol decreased lipid peroxidation levels and protected against neuronal damage in the substantia nigra region.</p><p><strong>Conclusion: </strong>Farnesol exhibits significant neuroprotective effects in rotenone-induced PD models, suggesting its potential as a therapeutic candidate for managing PD.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"14"},"PeriodicalIF":2.1,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, humanistic, and economic outcomes of Passiflora alata Curtis use in participants with mild to moderate anxiety: a non-randomized experimental study.","authors":"Thatiane Bárbara de Barros, Astrid Wiens, Tiago Marques Dos Reis","doi":"10.1007/s40199-026-00591-4","DOIUrl":"10.1007/s40199-026-00591-4","url":null,"abstract":"<p><strong>Background: </strong>Anxiety is a disorder treated through psychotherapy and/or pharmacotherapy. Passiflora alata Curtis is a herbal medicine used as a therapeutic alternative, although clinical evidence supporting its effectiveness in anxiety management is limited.</p><p><strong>Objectives: </strong>This study aimed to evaluate the clinical, humanistic, and economic outcomes in participants with anxiety treated with P. alata extract.</p><p><strong>Methods: </strong>This was an open-label, non-randomized, before-and-after experimental study. Inclusion criteria were: age ≥ 18 years and anxiety symptoms. The clinical outcome was assessed using the GAD-7 scale, comparing scores between baseline (t0) and the final follow-up (t3). The humanistic outcome was assessed using the TSQM, applied 15 days after treatment initiation and again at t3. The economic outcome consisted of analyzing direct treatment-related costs.</p><p><strong>Results: </strong>P. alata demonstrated clinical effectiveness in 29 participants (96.7%). TSQM results indicated a perceived improvement in health status within the first weeks. Regarding economic outcomes, differences were observed between the protocols that included P. alata and the conventional treatments offered by the Brazilian Unified Health System.</p><p><strong>Conclusion: </strong>It was concluded that the use of P. alata extract for anxiety management is a potential therapeutic alternative for incorporation into the Brazilian Unified Health System.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"12"},"PeriodicalIF":2.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12873022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-derived compounds as potential candidates for atrial fibrillation drug discovery: A review on phytochemicals with atrial-selective activity.","authors":"Bayan Azizi, Danesh Soltani, Arian Tavasol, Reza Hojjatifard, Pouria Delbari, Parisa Firoozbakhsh, Roja Rahimi, Ali Vasheghani-Farahani","doi":"10.1007/s40199-025-00586-7","DOIUrl":"10.1007/s40199-025-00586-7","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"13"},"PeriodicalIF":2.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12873047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of metformin's effect on 5-fluorouracil-induced cardiotoxicity through cellular protection.","authors":"Nahlah Fahad Alreshidi, Reham Abdullah Al-Dhelaan, Amjad Yousuf, Nihal Almuraikhi, Helal G Alanazi, Thamer Alsufayan, Musaad B Alsahly, Malik Bader Alazzam","doi":"10.1007/s40199-025-00589-4","DOIUrl":"10.1007/s40199-025-00589-4","url":null,"abstract":"<p><strong>Background: </strong>5-Fluorouracil (5-FU) is a chemotherapeutic agent used primarily to treat various cancers. While it has been successful in improving cancer survival rates, 5-FU is also known to be cardiotoxic. Treatment options for patients experiencing 5-FU-induced cardiotoxicity are limited to standard heart failure medications.</p><p><strong>Objectives: </strong>This study aims to investigate how metformin can reduce oxidative stress, apoptosis, and mitochondrial dysfunction in human cardiac myocyte (HCM) cells.</p><p><strong>Methods: </strong>The optimal doses of 5-FU were determined using the MTT assay. Following exposure to 5-FU, HCM cells were treated with metformin for 48 h. The study measured the levels of reactive oxygen species (ROS), glutathione (GSH), and the activity of superoxide dismutase (SOD). Additionally, cytochrome c release and mitochondrial membrane potential were assessed in HCM cells. The expression levels of BAX and Bcl-2 were also examined, along with the activity of Caspase-3.</p><p><strong>Results: </strong>The findings indicated that 5-FU significantly increased ROS levels, decreased GSH levels, and reduced SOD activity-effects that were mitigated by metformin. Furthermore, 5-FU markedly increased apoptosis and induced mitochondrial dysfunction, both of which were significantly reduced by metformin in a dose-dependent manner in HCM cells.</p><p><strong>Conclusion: </strong>According to the present study results, metformin, through a reduction in oxidative stress, apoptosis, and mitochondrial malfunction, can have therapeutic potential in HCM cells toxicity induced by 5-FU.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"11"},"PeriodicalIF":2.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of physical activity on epileptic seizures and consequentlearning and memory impairment in electrical amygdala kindling model.","authors":"Abbas Kebriaeezadeh, Reza Zaferi, Mohammad Sharifzadeh, Javad Mirnajafi-Zadeh, Ghorban Taghizadeh, Hassan Gheibi, Mahmoud Rezaei","doi":"10.1007/s40199-025-00583-w","DOIUrl":"10.1007/s40199-025-00583-w","url":null,"abstract":"<p><strong>Background: </strong>A recent body of evidence has suggested regular exercise as a promising complementary therapeutic strategy in the management of epilepsy and its related cognitive impairments.</p><p><strong>Objectives: </strong>To put it to the test, our study aimed to comparatively examine the effects of physical exercise, low and high doses of levetiracetam, or the combination of both on amygdala electrical kindling-induced epilepsy in rats, as well as the consequent learning and memory impairments.</p><p><strong>Methods: </strong>Male Wistar rats were randomly divided into ten groups (n = 7 per group) as the following: (I) Control (without kindling and exercise), (II) Lev (rats were received 54 mg/kg of levetiracetam without kindling and exercise), (III) Ex (rats were subjected to exercise without kindling), (IV) Ex-K (rats were subjected to preventive exercise before kindling), (V) K (rats were subjected to kindling without any intervention), (VI) K-Ex (rats were subjected to exercise after kindling), (VII) K-L lev (rats were received 27 mg/kg levetiracetam after kindling), (VIII) K-H lev (rats were received 54 mg/kg levetiracetam after kindling), (IX) K-Ex-L lev (subjected to exercise and receiving a low dose of levetiracetam after kindling), and (X) K-Ex-H lev (rats were subjected to exercise and receiving a high dose of levetiracetam after kindling). After the kindling procedure and interventions, the seizure parameters, including dADD, S₁L, S₂L, S₃L, S₄L, S₅L, Max S5D, and Max ADD, were recorded, and seizure-related behavioral changes were evaluated using the MWM test.</p><p><strong>Results: </strong>Our findings showed that in all therapeutic interventional groups, including Ex, L lev, H lev, and their combination (Ex-L lev and Ex-H lev), there was a substantial reduction in parameters, including seizure stages, seizure duration, and dADD. In contrast, there was a significant increase in the mean delay time or latency from electrical stimulation to the onset of stages 1, 2, and 3 of seizure (S₁L, S₂L, and S₃L), and all groups were significantly different from the kindling group. Moreover, the kindling-induced spatial memory and learning deficit was remarkably ameliorated by preventive exercise, Ex, L lev, H lev, and their combination.</p><p><strong>Conclusion: </strong>Our study reveals that, in conjunction with levetiracetam, regular exercise can ameliorate the intensity and frequency of amygdala electrical kindling-induced epileptic seizures, as well as the consequent spatial memory and learning impairments.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"10"},"PeriodicalIF":2.1,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12847565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Falcarindiol induces apoptosis, ROS accumulation, and cell cycle arrest via EGFR/mTOR pathway modulation: an integrated in silico and in vitro study in cervical cancer.","authors":"Ganesh Timalsina, Bishnu Prasad Parida, Megha Radhakrishnan, Tuliam Khoiyang, Sunita Singh, Gopeshwar Narayan","doi":"10.1007/s40199-025-00588-5","DOIUrl":"10.1007/s40199-025-00588-5","url":null,"abstract":"<p><strong>Background: </strong>Falcarindiol, a bioactive polyacetylene, has shown cytotoxic effects in several cancers including breast, colorectal, and oral squamous carcinoma, but its pharmacological actions in cervical cancer are not well defined.</p><p><strong>Objectives: </strong>This study aims to integrate in silico approaches to define the multi-target pharmacological mechanisms of falcarindiol in cervical cancer, including ADMET profiling, network pharmacology, target prioritization, and molecular docking especially of EGFR/mTOR associated signaling pathways. Simultaneously, the study aims to experimentally verify the anticancer activity of falcarindiol in cervical cancer cells by examining its impacts on cell viability, apoptosis, mitochondrial dysfunction, reactive oxygen species generation, senescence induction, and cell cycle regulation.</p><p><strong>Methods: </strong>Pharmacokinetic and toxicity properties were evaluated using in silico ADMET profiling. Potential molecular targets and signaling pathways were identified from integrated databases, with hub genes prioritized by protein-protein interaction analysis. Protein-ligand binding was assessed through docking. Gene expression and prognostic significance were analyzed using public cancer datasets. Functional effects of falcarindiol were validated in HeLa and SiHa cervical cancer cells by MTT assay, Annexin V/PI, and AO/PI staining, mitotracker intensity, H₂DCFDA fluorescence, β-galactosidase staining, and cell cycle analysis.</p><p><strong>Results: </strong>Falcarindiol demonstrated favorable ADMET properties and low predicted toxicity. Target prioritization identified EGFR, ERBB2, mTOR, MMP9, and CASP3 as central nodes, with strong interactions confirmed for EGFR and mTOR. Expression analyses revealed upregulation and hypomethylation of these genes in cervical cancer. Falcarindiol reduced viability (IC50 ~ 125-150µM), induced apoptosis, disrupted mitochondrial membrane potential, increased ROS production, and caused G₀/G₁ arrest in vitro. Senescence was also enhanced in treated cells.</p><p><strong>Conclusion: </strong>Falcarindiol exerts multi-targeted pharmacological actions in cervical cancer by modulating EGFR/mTOR signaling and apoptotic pathways, supporting its potential as a therapeutic lead compound.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"7"},"PeriodicalIF":2.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials.","authors":"Abdel Rahman Jaber, Jihad Abu Zayed, Zaid Alabed, Ja'far Zapen, Hazem Ayesh","doi":"10.1007/s40199-026-00590-5","DOIUrl":"10.1007/s40199-026-00590-5","url":null,"abstract":"<p><strong>Background: </strong>Cholesteryl ester transfer protein (CETP) inhibitors, specifically anacetrapib and obicetrapib, have shown strong lipid-modifying effects by lowering low-density lipoprotein cholesterol (LDL-C) and altering other lipid parameters. However, comparative evidence on their relative efficacy and safety is limited.</p><p><strong>Objectives: </strong>To compare the efficacy and safety of anacetrapib and obicetrapib.</p><p><strong>Methods: </strong>We systematically searched PubMed, Scopus, Web of Science, Cochrane Central Register, and ClinicalTrials.gov. The protocol was registered at OSF ( https://doi.org/10.17605/OSF.IO/VRP8Y ). The primary outcome was change in LDL-C; secondary outcomes included high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol, triglycerides, lipoprotein (a), apolipoprotein B (ApoB), apolipoprotein AI (ApoAI), apolipoprotein E (ApoE), incidence of adverse events, serious adverse events, and discontinuation. A frequentist random-effects network meta-analysis was performed using the netmeta package in R, with placebo as reference.</p><p><strong>Results: </strong>Ten randomized controlled trials (2,937 patients) were included. Obicetrapib showed the most significant reduction in LDL-C (MD -33.63 mg/dL; 95% CI [-44.10, -23.16]) and the most significant increase in HDL-C (MD 154.33 mg/dL; 95% CI [132.73, 175.93]), outperforming anacetrapib. Both drugs comparably reduced non-HDL-C, ApoB, and Lp(a). Obicetrapib was associated with greater increases in ApoA1 and ApoE, while anacetrapib lowered triglycerides more effectively. Obicetrapib had the lowest risk of overall adverse events (RR 0.69; 95% CI [0.49, 0.99]) and ranked favorably for serious adverse events and discontinuation.</p><p><strong>Conclusion: </strong>Both agents effectively reduced LDL-C levels, with obicetrapib demonstrating superior efficacy compared to anacetrapib. Additionally, both treatments demonstrated favorable safety profiles. These findings underscore the potential of CETP inhibitors as promising therapeutic options for patients with dyslipidemia.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"34 1","pages":"9"},"PeriodicalIF":2.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}